亿帆医药上半年净利3.04亿元，同比增长19.91%

Core Viewpoint - Yifan Pharmaceutical (002019) reported a slight increase in revenue for the first half of 2025, while net profit saw a significant growth, indicating a positive trend in profitability despite modest revenue growth [1] Financial Performance - The company achieved an operating income of 2.635 billion yuan in the first half of 2025, representing a year-on-year growth of 0.11% [1] - The net profit attributable to shareholders was 304 million yuan, reflecting a year-on-year increase of 19.91% [1] Business Operations - Yifan Pharmaceutical is primarily engaged in the research, development, production, sales of pharmaceutical products, vitamins, and high polymer materials, as well as drug promotion services [1]